Aldosterone and the mineralocorticoid receptor contribute to resistant hypertension and cardiovascular mortality, and mineralocorticoid receptor antagonists effectively reduce these complications. Their use is limited in certain populations with a higher risk of hyperkalemia or renal dysfunction. This review will highlight recent developments in extra-renal mineralocorticoid receptor research and the development of novel mineralocorticoid receptor antagonists.
INTRODUCTION
Syndromes of mineralocorticoid excess led to the discovery of aldosterone in the 1950s, and the genetic characterization of monogenic hypertension has repeatedly demonstrated the importance of aldosterone and renal sodium reabsorption in the genesis of hypertension. Recent studies have changed our view of traditional mineralocorticoid receptor activation to include actions of aldosterone and the mineralocorticoid receptor in extra-renal tissues, such as vascular smooth muscle and cardiomyocytes. Traditional mineralocorticoid receptor antagonists (MRAs) are effective treatments for congestive heart failure and resistant hypertension [1] [2] [3] [4] , but the risk posed by hyperkalemia and renal dysfunction limits broad applications in the clinical setting. Because MRAs are beneficial even in highrisk individuals [5] , withholding this therapy could deprive patients with the greatest need of effective treatment. It remains to be seen if next-generation MRAs can minimize these risks while maintaining their cardiovascular benefits, but recent drug developments show promise toward achieving this goal [6 & ,7].
PATHOLOGIC CONSEQUENCES OF EXTRA-RENAL MINERALOCORTICOID RECEPTOR ACTIVATION
Aldosterone is critical for maximal renal sodium reabsorption during volume depletion and for urinary potassium excretion during potassium excess. These effects are mediated primarily by mineralocorticoid receptor activation in the distal nephron segments, which increases epithelial sodium channel expression and activity. In the cardiovascular system, the mineralocorticoid receptor is expressed in cardiomyocytes, vascular endothelium, and vascular smooth muscle in which it contributes to injury independent of renal effects. Administration of aldosterone and high-salt diet induces cardiac hypertrophy with perivascular inflammation and fibrosis via mineralocorticoid receptor activation, suggesting a direct effect of aldosterone and mineralocorticoid receptor activation in extra-renal tissues independent of blood pressure (BP).
In the Randomized Aldactone Evaluation Study, spironolactone reduced cardiovascular mortality and rehospitalization rates by 30% in patients with severe congestive heart failure [2] . The selective MRA eplerenone also reduced cardiovascular mortality by 17% in patients with acute myocardial infarction complicated by heart failure [1] . These benefits occurred in the absence of BP reduction, stimulating further research to determine the mechanism of extra-renal mineralocorticoid receptor-induced injury. Using Cre recombinase technology, investigators have demonstrated that mineralocorticoid receptor activation within vascular smooth muscle, cardiomyocytes, and monocytes or macrophages directly contributes to adverse cardiovascular consequences [8,9,10 & ,11] . Tissue-specific mineralocorticoid receptor deletion in smooth muscle cells prevents age-related BP elevation and vascular remodeling [10 & ] and prevents injury-induced vascular smooth muscle cells hypertrophy [8] . After experimental myocardial infarction, cardiac-specific mineralocorticoid receptor inactivation reduced cardiac hypertrophy, diastolic dysfunction, and pulmonary edema [12] .
TRADITIONAL MINERALOCORTICOID RECEPTOR ANTAGONISTS
Spironolactone is the prototypical steroidal MRA, but has nonselective progesterone receptor agonistic and androgen receptor (AR) antagonistic activity ( Table 1 ). This nonselectivity contributes to the unwelcome side-effects of gynecomastia, menstrual irregularities, and decreased libido, respectively. Spironolactone causes breast pain or gynecomastia in men in a dose-dependent and timedependent manner, with an incidence of 10% after 25 mg daily, and as high as 52% after 150 mg daily over 2 years [2, 20] . Clinically approved MRAs are structurally similar spirolactones, possessing a g-lactone ring at the C17 position and various substituents attached to the C7 steroid carbon [21] . Eplerenone is the most selective MRA without significant progesterone or androgen activity, but at the expense of potency compared with spironolactone (Table 1) .
Although the off-target side-effects are reduced during eplerenone versus spironolactone treatment [22] , side-effects related to renal mineralocorticoid receptor inhibition limit their use in patients at high risk for hyperkalemia. Those with heart failure with
KEY POINTS
Although the renal mineralocorticoid receptor stimulates sodium reabsorption and potassium excretion and contributes to hypertension, activation of the mineralocorticoid receptor in extra-renal tissues also contributes to the pathogenesis of cardiovascular injury.
Tissue-specific mineralocorticoid receptor knockout animals have demonstrated an important role for extrarenal mineralocorticoid receptor in learning, vascular injury and potassium homeostasis.
Selective nonsteroidal mineralocorticoid receptor antagonists have been recently developed and demonstrate effectiveness in early clinical trials. the highest risk of mortality also carry the highest risk for hyperkalemia, namely those with diabetes and renal dysfunction. The incidence of hyperkalemia during mineralocorticoid receptor antagonism is relatively low in highly controlled clinical trial settings [1,2,5,23,24 && ], but application to broader populations without close monitoring has been associated with increased hospitalization rates for hyperkalemia [25] . In general practice, spironolactone was discontinued in 33% of patients with heart failure, primarily because of hyperkalemia (10%) and worsening renal function (10%) [26] . Although a decline in renal function is relatively common in patients with ischemic events complicated by heart failure, the cardiovascular benefits of mineralocorticoid receptor antagonism persist [5, 27] . Therefore, MRAs are needed which would allow administration to patients with the highest risk of hyperkalemia, such as those with chronic kidney disease, diabetes, and elevated baseline potassium or the elderly. Nonsteroidal MRAs are being developed with these goals in mind.
Over the past decade, pharmaceutical companies have launched drug-discovery programs for nonsteroidal MRAs using various high-throughput screening methods, which has led to the identification of several drug classes which possess MRA activity [13, [16] [17] [18] [19] 28, 29] . Review of published patent applications demonstrates that additional compounds have been identified but not yet published in the scientific literature. Compounds with detailed pharmacologic potency and demonstrated in-vivo effectiveness will be discussed further ( Fig. 1 ).
DIHYDROPYRIDINE-DERIVED MINERALOCORTICOID RECEPTOR ANTAGONISTS
Dietz et al. [30] demonstrated that most clinically approved dihydropyridine calcium channel blockers possess the ability to block aldosterone-induced mineralocorticoid receptor activation in vitro using luciferase reporter assays. The effects of nimodipine, felodipine, and nitrendipine were particularly effective, achieving complete inhibition, although at suprapharmacologic concentrations. The concentration at which nimodipine achieves 50% inhibition (i.e., the IC 50 ) was within the range achieved in humans using standard clinical dosing. Nifedipine was somewhat less effective, whereas amlodipine possessed the lowest potency. The IC 50 for nifedipine was 0.7 nM, although a maximum concentration of only 0.3 nM is typically achieved after chronic oral administration of 90 mg of sustained-release nifedipine (package insert). The predominant clinical effect of these agents is produced by their calcium channel blocking effect, rather than MRA activity. Other studies have confirmed the MRA activity of calcium channel blockers at micromolar concentrations, but also suggest that they nonselectively inhibit multiple nuclear receptors [17] .
Modification of these existing compounds has aided the development of novel nonsteroidal MRAs, some of which have proven effective in preclinical and clinical trials. Using the dihydropyridine structure, compounds have been modified to remove calcium channel inhibitory activity and to increase mineralocorticoid receptor selectivity, pharmacokinetic suitability, and bioavailability [31] . One compound, (R)-7d, met these requirements and was used in further in-vivo studies. When given to Dahl saltsensitive rats at 60 mg/kg/day, compound (R)-7d attenuated salt-induced hypertension to the same extent as eplerenone.
Fagart et al. [17] similarly identified dihydropyridines as MRAs using a high-throughput screening method, and characterized BR-4628 as a selective nonsteroidal MRA, although still with some progesterone receptor (PR) agonist activity. The independent discovery and optimization of multiple dihydropyridine compounds provides further proof of concept that dihydropyridine derivatives can function as MRAs. BR-4628 was also active in vivo when given orally to rats, as measured by the urinary sodium to potassium ratio [17] . In preclinical studies, BR-4628 prevented deoxycorticosterone or saltinduced kidney injury independent of hypertension in vivo [32] and prevented fibrotic cardiomyocyte remodeling in vitro [33] .
Further drug optimization has led to the development of BAY94-8862, which is more potent (IC 50 18 nM) and has no measurable activity at the PR, AR, glucocorticoid receptor (GR), or estrogen receptor (ER) in vitro [16] . This compound increased the urinary sodium, or potassium ratio, and demonstrated evidence of cardiovascular benefit in preclinical studies. BAY94-8862 has become the first nonsteroidal to advance in clinical trials (the MinerAlocorticoid Receptor Antagonist Tolerability Study) to investigate whether it can be safely used in high-risk study participants with heart failure, reduced ejection fraction less than 40%, and renal dysfunction [34, 35] .
The initial phase I study enrolled study participants in part A with mild renal insufficiency [estimated glomerular filtration rate (eGFR) 60-90 ml/min/1.73m 2 by the modification of diet in renal disease (MDRD) equation] in a randomized, placebo-controlled parallel trial (n 16 each arm) to BAY94-8862 (either 2.5, 5.0, or 10 mg daily) or placebo for 4 weeks to assess safety. The drug was well tolerated in this initial phase study, with mildly elevated potassium in one study participant who did not require treatment or discontinuation. In part B, the study enrolled 393 study participants with moderate renal insufficiency (eGFR 30-60 ml/min/ 1.73m 2 ) randomized to either BAY94-8862 (either 2.5, 5.0, or 10 mg daily), placebo, or open-label spironolactone for 4 weeks. Spironolactone was given 25 mg daily for 14 days, and then increased to 50 mg daily if serum potassium remained less than 4.8 mEq/l. BAY94-8862 increased serum potassium at 4 weeks in a dose-dependent manner, but to a lesser degree than spironolactone and produced no more renal dysfunction than placebo. It also did not alter BP or plasma aldosterone to the same extent as spironolactone. At the same time, urine albumin or creatinine and circulating N-terminal B-type natriuretic peptide appeared to improve to a similar degree during BAY94-8862 10 mg daily. On the basis of these results, this drug has entered phase II studies for the treatment of diabetic nephropathy.
PYRAZOLINE-DERIVED COMPOUNDS
Using a high-throughput screening method, a pyrazoline compound has been discovered to have MRA activity [13, 15] . Pyrazoline-related compounds had previously been described as binding to other steroid nuclear receptors, and chemical optimization led to the identification of PF-03882845. This compound is highly selective for the mineralocorticoid receptor without significant effects on the AR, PR, or GR in vitro. PF-03882845 effectively reduced BP in Dahl salt-sensitive rats, preventing renal injury assessed by histology and albuminuria to the same or greater extent at 40 mg/kg/day compared with eplerenone [15] . There was a trend for serum potassium to increase to a lesser extent during PF-03882845 treatment. Although this compound reached clinical testing for diabetic nephropathy, early studies were terminated because of 'poor recruitment and a shift in business strategy' (ClinicalTrials.gov NCT01488877). Further refinement of this compound also led to the identification of compound (R)14c, which has improved mineralocorticoid receptor potency, selectivity over PR, and increased solubility compared with PF-03882845 [13] . Compound (R)14c increases the urinary sodium, or potassium ratio in rats, suggesting effective mineralocorticoid receptor antagonism in vivo, although its effect on cardiovascular and renal injury has not yet been proven.
SULFONAMIDE-DERIVED BENZOXAZINETHIONES
Further evidence that nonsteroidal MRAs can prevent cardiovascular injury is provided by the sulfonamide SM-368229 [19, 36, 37] . SM-368229 reduced BP, ventricular hypertrophy, and renal injury in spontaneously hypertensive rats and aldosteronetreated rats without increasing serum potassium [36, 37] . Further studies in potassium-loaded rats demonstrated no increase in serum potassium during chronic SM-368229 administration [36] .
Can the risk of hyperkalemia be separated from cardiovascular benefit of MRAs?
Clinical applicability of MRAs to patients with renal dysfunction is limited because of hyperkalemia, and if new agents can achieve similar cardiovascular benefits with a reduced hyperkalemia risk, this would significantly expand the target population. It is well known that aldosterone increases urinary potassium excretion which causes hypokalemia in the setting of inappropriate aldosterone excess.
A number of mechanisms have been proposed by which nonsteroidal MRAs could avoid the risk of hyperkalemia [6 & ]. Spironolactone and eplerenone accumulate in renal tissue to a greater extent than cardiovascular tissue, and several publications have suggested that the novel drug has a more balanced tissue distribution. However, this alone may not prevent the risk of hyperkalemia. Aldosterone also affects potassium handling via extra-renal effects in skeletal muscle and other tissues. Aldosterone and the mineralocorticoid receptor directly affect skeletal muscle potassium transport in chronic adaptation to a high potassium diet [38] [39] [40] . Other mineralocorticoids such as deoxycorticosterone, but not glucocorticoids, also stimulate skeletal muscle potassium uptake which is prevented by mineralocorticoid receptor antagonism with spironolactone [40] .
Another mechanistic possibility is differential effects on coactivators in different tissues. Steroidal MRAs and BR-4628 bind in the ligand-binding domain of the mineralocorticoid receptor, although BR-4628 has a bulky side chain that induces conformational changes. These changes can alter recruitment of coactivators and corepressors, thus altering the stability, nuclear translocation, and activation. Similar molecular mechanisms are responsible for selective estrogen receptor modulators. More research is needed to identify tissue-specific mineralocorticoid receptor partners which contribute to cardiovascular injury, along with further drug modification. However, these findings indicate the future possibility of selectively modifying cardiovascular mineralocorticoid receptor responses while minimizing the risk of renal complications.
CONCLUSION
The critical challenge for nonsteroidal MRAs will be to maintain the cardiovascular effectiveness of nonsteroidal MRAs, namely for heart failure and resistant hypertension, while reducing side-effects. If successful, the decreased risk of hyperkalemia could expand the use of these agents into populations at high risk of complications, such as those with renal insufficiency. This could further expand a role for these agents in diabetic nephropathy. Although spironolactone in addition to standard care effectively reduces proteinuria in diabetic nephropathy [41] , its effectiveness in reducing progression to death, dialysis, or need for transplantation has not, and likely will not be determined. A significant proportion of patients with diabetic nephropathy progress to renal failure or die of cardiovascular complications. Furthermore, diabetic renal disease is the leading cause of renal failure, which is among the costliest diseases in the United States healthcare system. Therefore, reduction in the number of patients requiring dialysis would have significant clinical and cost benefits. The initial studies of nonsteroidal MRAs are being conducted in patients with diabetic nephropathy, a population with a markedly elevated risk of cardiovascular complications.
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